Skip to content
No results
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Stategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • AT-101
    • PCV-001
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Stategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • AT-101
    • PCV-001
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx

ESMO 2016 Poster 1

May 2, 2016

ESMO-2016-Poster-1

Share This Post

XFacebookLinkedInMessengerWhatsApp

Posts navigation

← Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2) →

More Posts

IngenOx Therapeutics Receives New Patents for Compounds Inhibiting PRMT5

July 6, 2023

IngenOx Therapeutics Zabadinostat Approved by Hong Kong Drug Office to Start Liver Cancer Clinical Trial

April 24, 2023

IngenOx Therapeutics Drug Zabadinostat Enhances the Immune Response

March 7, 2023
IngenOx
  • Registered Address: Magdalen Centre Oxford Science Park Robert Robinson Avenue Oxford, OX4 4GA
  • Email: enquiries@ingenOx.com

Products

  • Zabadinostat (CXD101)
  • AT-101
  • PCV-001
  • Pipeline

About Us

  • About
  • Executive Team
  • Board of Directors
  • Strategic Collaborations

Useful Links

  • Careers
  • Press Releases
  • Publications
  • Contact

Copyright © 2023 

  • Anti-Slavery Statement
  • Privacy Statement